DESCRIPTION Cyproheptadine HCl USP is an antihistaminic and antiserotonergic agent .
Cyproheptadine hydrochloride USP is a white to slightly yellowish crystalline solid , with a molecular weight of 350 . 89 , which is soluble in water , freely soluble in methanol , sparingly soluble in ethanol , soluble in chloroform , and practically insoluble in ether .
It is the sesquihydrate of 4 - ( 5 H - dibenzo [ a , d ] cyclohepten - 5 - ylidene ) - 1 - methylpiperidine hydrochloride .
The molecular formula of the anhydrous salt is C 21 H 21 N • HCl and the structural formula of the anhydrous salt is : [ MULTIMEDIA ] C 21 H 21 N • HCl M . W . 350 . 89 Cyproheptadine hydrochloride USP is available for oral administration in 4 mg tablets .
Inactive ingredients include : lactose monohydrate , magnesium stearate , microcrystalline cellulose , and sodium starch glycolate .
[ MULTIMEDIA ] CLINICAL PHARMACOLOGY Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects .
Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine , respectively , for receptor sites .
Pharmacokinetics and Metabolism After a single 4 mg oral dose of 14 C - labelled cyproheptadine HCl in normal subjects , given as tablets , 2 to 20 % of the radioactivity was excreted in the stools .
Only about 34 % of the stool radioactivity was unchanged drug , corresponding to less than 5 . 7 % of the dose .
At least 40 % of the administered radioactivity was excreted in the urine .
No detectable amounts of unchanged drug were present in the urine of patients on chronic 12 to 20 mg daily doses .
The principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine .
Elimination is diminished in renal insufficiency .
Cyproheptadine HCl Tablets USP 4 mg [ MULTIMEDIA ] [ MULTIMEDIA ] [ MULTIMEDIA ] [ MULTIMEDIA ]
